Drug Channels

DECEMBER 3, 2024

Minnesota just released the industry‘s first ever mandated financial report on the 340B Drug Pricing Program. It’s time to pay attention to the money behind the 340B curtain. Below, I do a wicked deep dive into the data and highlight crucial implications about spending, profits, pharmacies, plans, patients, program integrity, and more.

Drug Pricing 52

Drug Pricing Hospitals 52

BioPharma Dive

JULY 9, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Actithera draws new investors to radiopharma drug pitch The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Drug Pricing 62

Drug Pricing Compounding Immunity Immunization 62

Pharmacy Times

JUNE 23, 2025

This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs. In 2022, CMS reevaluated 505(b)(2) drugs in relation to section 1847A of the Social Security Act (SSA).

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Dosage Hospitals 26

Putting Patients First Blog

MAY 6, 2025

National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey. 2 (2022): e314e322. Food and Drug Administration, Importing Biologics and CBER Regulated Products. Journal of Oncology Practice 18, no. 6 Avalere Health, Majority of API in U.S.

Pharmaceutical Manufacturing 52

Pharmaceutical Manufacturing Generic Medicine Drug Pricing Hospitals 52

Pharma Marketing Network

MAY 11, 2025

accelerates its crackdown on drug pricing through new legislation and regulatory enforcement, pharma companies in China, India, Japan, and South Korea are feeling the ripple effect. This move marked a major shift in how drug pricing is managed in the United Statesa market that contributes significantly to global pharma revenues.

Drug Pricing 59

Drug Pricing Biosimilars Communication Immunity 59

Pharmaceutical Commerce

JUNE 9, 2025

during the 2024-2025 RSV season compared to the 2022-2023 season, per data presented at the 43rd Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). For instance, an immunization program that was executed in Spain using Beyfortus reportedly reduced infant hospitalizations due to RSV by 69.0%

Drug Pricing 52

Drug Pricing Vaccines Immunity Immunization 52

Pharmaceutical Technology

JUNE 9, 2025

In Slovakia, reforms in 2022 were to introduce improvements to the reimbursement rates in the market by creating a systemic pathway for negotiations and managed-entry agreements. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Communication 52

Communication Hospitals Drug Pricing Packaging 52

Beckers Hospital Review

JULY 9, 2025

A federal judge rejected Johnson & Johnson’s challenge to block its proposed rebate model under the 340B Drug Pricing Program. based UW Health is not legally required to engage in collective bargaining with its nurses, upholding November 2022 decisions from the Wisconsin Employment Relations Commission.

Hospitals 52

Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 11, 2025

The rising volume of clinical trials increases demand and competition for patients The number of oncology assets in the clinical development pipeline has increased by 13% annually over five years (2018-2022) 1. 10 “That is simply unsustainable,” Kent Thoelke argues, especially as drug pricing pressures mount in major markets.

Drug Pricing 52

Drug Pricing Hospitals Medical Records Drug Development 52

Pharmaceutical Technology

JULY 4, 2025

A recent report by GlobalData projects that the share of global drug sales under patent protection will decline by 2030. Only 4% of global drugs sales will have patent protection, compared to 12% and 6% in 2022 and 2024. Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi.

Biosimilars 52

Biosimilars Chemotherapy Packaging Communication 52

Pharmacy Times

JUNE 12, 2025

Trump signed an executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” with the objective of lowering drug prices, namely on branded drug products, for American consumers. How Does Drug Pricing in the US Compare With Other Countries? REFERENCES 1.

Pharmacy Technician 26

Pharmacy Technician Community Pharmacies Drug Pricing Hospitals 26

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

Pharmaceutical Technology

JULY 2, 2025

According to GlobalData epidemiologists, 437,425 people were on PrEP in the US in 2022, but this could be considerably higher, highlighting that drugs that help protect against HIV are not being maximised in the country. How will RFK Jr’s American dream for vaccines play out?

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Packaging Communication Hospitals 52

Pharmaceutical Technology

JUNE 6, 2025

In 2022, Axsome paid $53m up front to acquire Sunosi from Jazz Pharmaceuticals. A drug with a recent approval extension in the US, though not the UK, was Supernus Pharmaceuticals’ Qelbree (viloxazine extended-release capsules). Certain patients with obstructive sleep apnoea (OSA) are also eligible to take the medication.

Communication 52

Communication Hospitals Drug Pricing Packaging 52

Pharmaceutical Commerce

JUNE 13, 2025

The Trump Administration has revived the most-favored nation (MFN) drug pricing model as a seven-year test, which would tie US drug prices to the lowest prices paid by certain OECD countries—an approach previously blocked by courts. Concerns over price controls. What is MFN model pricing? China wins?

Drug Pricing 59

Drug Pricing Biosimilars Pharmaceutical Companies Pharmaceutical Companies 59

Drug Channels

APRIL 2, 2025

Minnesota just released the industrys first ever mandated financial report on the 340B Drug Pricing Program. Click here to see the original post from December 2024. Its time to pay attention to the money behind the 340B curtain.

Drug Pricing 52

Drug Pricing Hospitals 52

Pharmaceutical Technology

JULY 16, 2025

The drugmaker is also seeking a positive decision for the antibody-drug conjugate (ADC) used in combo with Bristol Myers Squibb’s Pomalyst and dexamethasone in the same proposed patient group. Although initially getting ahead in the now lucrative ADC market, GSK pulled the drug in 2022 after confirmatory trial shortcomings.

Documentation 52

Documentation Communication Packaging Hospitals 52

Pharmaceutical Technology

JULY 14, 2025

Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma Formulate Faster. Find out more Lenacapavir was first approved in 2022 under the brand name Sunlenca for the treatment of HIV infection in adults with multi-drug resistance.

Vaccines 52

Vaccines Packaging Hospitals Communication 52

Pharmaceutical Technology

JULY 2, 2025

By GlobalData Learn more about Strategic Intelligence Expanding on their existing agreement from 2022, Sanofi has exercised an option within the partnership that allows it to select a third SAFEbody discovery programme. How will RFK Jr’s American dream for vaccines play out? Don’t let policy changes catch you off guard.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

BioPharma Dive

JUNE 11, 2025

The company scrapped its initial drug program in 2022 and changed course two years later when a second prospect disappointed. Like many other biotechnology firms, it’s seen its stock price fall significantly during a sector-wide pullback, with shares losing more than three quarters of their value since 2020. TechTarget, Inc.s

Drug Pricing 108

Drug Pricing Immunity Immunization Drug Development 108

Drug Channels

JANUARY 14, 2025

During my recent Drug Channels Outlook 2025 video webinar, I tackled a wide range of crucial topicsincluding the controversial 340B Drug Pricing Program. As I explain in this video excerpt, we may finally see reform of this rapidly expanding program. Click here if you cant see the video below.

Drug Pricing 52

Drug Pricing Hospitals 52

Pharmaceutical Technology

JULY 18, 2025

This marks a significant setback for the UK-based pharma company, which is aiming to regain approval of the therapy after it was pulled from the US market in 2022 due to concerns raised by late-stage trial data. How will RFK Jr’s American dream for vaccines play out? Don’t let policy changes catch you off guard.

Communication 52

Communication Packaging Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 15, 2025

Christophe Bourdon, who was appointed CEO in 2022 and tasked with turning the fortunes of the company around, has made no secret of public listing plans. How will RFK Jr’s American dream for vaccines play out? Adding Spevigo to its portfolio represents a strengthening of assets for dermatology specialist LEO.

Packaging 52

Packaging Communication Hospitals Vaccines 52

STAT

APRIL 15, 2025

President Trump unveiled a wide-ranging executive order on Tuesday that aims to lower drug prices, boost transparency into fees charged by middlemen, and limit Medicare payments for outpatient services provided by hospitals. The executive order outlines a plan to expand Medicare drug price negotiation.

Drug Pricing 330

Drug Pricing Hospitals 330

STAT

JULY 30, 2024

WASHINGTON — The deadline for announcing how much Medicare lowered drug prices in the first year of negotiation is Sept. In 2022, Democrats directed Medicare to negotiate drug prices for the first time as part of the Inflation Reduction Act. The first 10 drugs selected for negotiation accounted for $3.4

Drug Pricing 286

Drug Pricing 286

Drug Channels

MAY 21, 2025

Even more troubling, these fluctuations have led to unexpected increases in patients out-of-pocket expenseseven when a drugs price was declining. In many cases, the rate dips temporarily before snapping back to the standard 20%. These unpredictable coinsurance shifts are another example of the IRAs unintended consequences.

Drug Pricing 52

Drug Pricing 52

STAT

FEBRUARY 5, 2024

WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s Medicare drug price negotiation program managed to find themselves a Democratic co-sponsor — even though every single Democrat in Congress in 2022 voted for the legislation.

Drug Pricing 338

Drug Pricing 338

STAT

MARCH 31, 2023

At the same time, net prices health plans paid for medicines — after subtracting rebates, discounts, and fees — dropped by 0.4%. But again, after considering inflation, net prices actually fell 8.5%, compared with 8.2% in the third quarter of 2022. Continue to STAT+ to read the full story…

Drug Pricing 253

Drug Pricing 253

STAT

OCTOBER 21, 2024

30, five gave to Democratic candidates, even though Democratic lawmakers passed the most aggressive drug pricing reform in decades in 2022.    But of the six executives who donated to individual candidates between July 1 and Sept.   Continue to STAT+ to read the full story…

Drug Pricing 363

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 363

STAT

DECEMBER 23, 2024

WASHINGTON — Three large pharmaceutical companies left the brand-drug lobby PhRMA after the passage of Democrats’ drug pricing law in 2022. Following the exits, the organization collected $100 million less in annual membership dues, new tax filings show. Continue to STAT+ to read the full story…

Drug Pricing 302

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 302

STAT

DECEMBER 6, 2023

It is also the latest instance in a growing trend of pharmaceutical companies re-evaluating their memberships in large trade groups following a historic lobbying loss when Democrats passed a new drug-pricing reform law in August 2022.

Drug Pricing 267

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 267

STAT

JANUARY 17, 2023

retail drug purchases. Continue to STAT+ to read the full story…

Drug Pricing 267

Drug Pricing Hospitals 267

STAT

AUGUST 5, 2024

The Inflation Reduction Act, passed by Democrats in 2022, made several changes to Medicare’s drug benefit, known as Medicare Part D. All were aimed at lowering drug prices and drug costs for both seniors and the federal government.

Drug Pricing 297

Drug Pricing 297

STAT

DECEMBER 11, 2023

During 2022, drugmakers substantially raised prices on eight widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $1.2 billion last year, according to a new report.

Drug Pricing 357

Drug Pricing 357

STAT

OCTOBER 20, 2022

The Inflation Reduction Act of 2022 mandates that Medicare-covered drug sales will be protected from price increases that exceed inflation, but the mechanics of this “inflation penalty” have generated some confusion.

Drug Pricing 246

Drug Pricing 246

STAT

NOVEMBER 14, 2022

In this video, we chat with health policy and drug pricing researcher Hussain Lalani; Julia Joung, a molecular biologist developing genetic screening technologies; and Avinash Manjula Basavanna, who researches engineered living materials and has developed a printable ink made from bacteria.

Drug Pricing 241

Drug Pricing 241

STAT

OCTOBER 26, 2023

And after 20 years, they finally delivered on a promise to empower the federal government to lower drug prices in 2022. They have campaigned on passing health insurance reform, and then protecting it. But the remaining elephant in the room is hospital costs, which make up the biggest share of U.S. health care spending.

Hospitals 355

Hospitals Drug Pricing 355